Future treatments for hereditary hemorrhagic telangiectasia

Future treatments for hereditary hemorrhagic telangiectasia

Abstract Hereditary Hemorrhagic Telangiectasia (HHT), also known as Rendu-Osler syndrome, is a genetic vascular disorder affecting 1 in 5000–8000 individuals worldwide. This rare disease is characterized by various vascular defects including epistaxis, blood vessel dilations (telangiectasia) and art...

Full description

Bibliographic Details
Main Authors: Florian Robert, Agnès Desroches-Castan, Sabine Bailly, Sophie Dupuis-Girod, Jean-Jacques Feige
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Hereditary hemorrhagic telangiectasia
Vascular malformations
Bone morphogenetic protein signaling
Drug repositioning
Bevacizumab
Tacrolimus
Online Access:https://doi.org/10.1186/s13023-019-1281-4

Internet

https://doi.org/10.1186/s13023-019-1281-4

Similar Items